Everest Medicines to Release Full-Year 2024 Financial Results on March 26, 2025

SHANGHAI, Feb. 25, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical firm focused on discovering, developing, manufacturing, and bringing to market innovative therapies, has announced it will report its financial results for the complete year of 2024 ending on December 31, 2024, along with a business update on March 26, 2025. The Company will host a live conference call in both English and Mandarin on March 26, 2025 Beijing Time.

The English portion of the conference call is scheduled for 9:00 AM on March 26, 2025 Beijing Time (9:00 PM U.S. Eastern Time on March 25, 2025), while the Mandarin session will take place at 10:30 AM Beijing Time on the same day (10:30 PM U.S. Eastern Time on March 25, 2025).

Access conference calls via the following links:

For the English Session:

Time: 9:00 AM Beijing Time, Wednesday, March 26, 2025 (9:00 PM U.S. Eastern Time on March 25, 2025)

Pre-Registration Link: https://www.acecamptech.com/eventDetail/60522311

Webcast Link:
https://www.acecamptech.com/meeting_live/70524304/786503?event_id=60522311

Alternatively, participants can join the conference call using the following dial-in information:

For the Mandarin Session:

Time: 10:30 AM Beijing Time, Wednesday, March 26, 2025 (10:30 PM U.S. Eastern Time on March 25, 2025)

Webcast Link: https://s.comein.cn/3amz5di6

For alternative access, participants may also call using the below dial-in information:

The recorded English session will be accessible shortly after the call by visiting the Company’s website at http://www.everestmedicines.com.

About Everest Medicines

Everest Medicines is a biopharmaceutical organization dedicated to the discovery, development, manufacturing, and marketing of innovative pharmaceutical products and vaccines that cater to vital unmet medical issues for patients in Asian markets. The management team at Everest Medicines boasts extensive experience and a successful track record from leading global pharmaceutical firms and local Chinese pharmaceutical companies, specializing in high-quality discovery, clinical development, regulatory affairs, CMC, business development, and operations. Everest Medicines has developed a portfolio of potentially global first-in-class or best-in-class molecules in its key therapeutic areas of renal diseases, infectious diseases, and autoimmune conditions. For more details, please visit www.everestmedicines.com.

Story Continues

Forward-Looking Statements:

This press release may include forward-looking statements, encompassing descriptions regarding the intentions, beliefs, or current expectations of the Company or its officers concerning the Company’s operations and financial state, identifiable by terms such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” and similar expressions. These forward-looking statements are not assurances of future performance and entail risks and uncertainties, or other factors beyond the Company’s control and prediction. Thus, actual outcomes may differ from those indicated in the forward-looking statements due to various elements and assumptions, such as prospective changes and developments in our business, competitive circumstances, and political, economic, legal, and social conditions. The Company and its affiliates, directors, officers, advisors, or representatives bear no obligation and do not commit to amending forward-looking statements to represent new information, future events, or conditions emerging after the date of this release, unless mandated by law.

 

View original content: https://www.prnewswire.com/apac/news-releases/everest-medicines-to-announce-full-year-2024-financial-results-on-march-26-2025-302384522.html

SOURCE Everest Medicines